Clinican Guidance E-cigarette or Vaping Product Use Associated Lung Injury (EVALI)

PATIENT SYMPTOMS • shortness of breath• cough• fever•• chest pain

• nausea, vomiting

EXPOSURE HISTORY • History

of vapingin past 3months

Consider 1-4 below if patient reports any of the above symptoms or exposures.

1 PERFORM IMAGING • Chest X-ray and/or CT (as clinically indicated)

2 RULE OUT INFECTIOUS DISEASE

• Influenza test (PCR if available)• Respiratory virus panel or respiratory

pathogen panel (as clinically indicated and available)• Legionella and Strep pneumoniae urine antigen

(as clinically indicated)• Mycoplasma PCR (as clinically indicated and available)• Blood culture if febrile• Inflammatory markers/liver transaminases• CBC with differential and platelets• Other tests (as clinically indicated)

If BAL/biopsy performed (as clinically indicated)• Gram stain and bacterial cultures• Fungal stains/fungal cultures• Acid-fast bacilli smear and mycobacterial cultures• Respiratory virus or pathogen panel• Pneumocystis PCR or pneumocystis specific stain

(as clinically indicated)• Lipid Oil Red stain (if available)• Other tests as clinically indicated

3 TOXICOLOGY EVALUATION • Urine drug testing (as clinically indicated)*

4

OTHER TESTING FOR PULMONARY PROCESSES (as clinically indicated)

• Rheumatologic, malignancy, cardiac, etc.

5 REPORT TO UDOH - PH: 801-538-6191FAX: 801-538-9923 Email: epi@utah.gov

• For patients with abnormal radiographic findings; frequentfindings are bilateral patchy infiltrates on X-ray or ground- glass on CT.

• If clinical specimens collected, retain earliest blood and urine.• Retain BAL or biopsy if performed.

6

CONSIDER CORTICOSTEROIDS IF APPEARING TO BE VAPING LUNG INJURY

• Advise consultation with pulmonary specialist to determineneed for corticosteroids and dosing.

• If admitted, consider consultation with infectious diseasespecialist and further infectious disease workup that couldinclude endemic mycoses and other pathogens.

• Some clinicians have found it helpful to consult with anendocrinologist for patients prescribed high-dose steroidsfor longer durations.

7

CARE POST-DISCHARGE

• If outpatient, follow-up with patient within 48 hours todetermine if symptoms have progressed.

• When discharged, schedule follow-up with patient; consulta pulmonologist as necessary to assess recovery.

• Many cases have nicotine and other substance addition; inaddition, many cases are noted to have anxiety and/ordepression. Referral to specialists in these areas are animportant part of treatment.

• Patients with symptoms, but who do not have evidence ofdisease on imaging, should be counseled to return ifsymptoms progress.

*Per CDC Recommendations - Given the limitations of thesensitivity and specificity of urine drug screen, this decisionshould be left to the clinician.

Reprinted with permission from the Minnesota Department of Health.

Clinical presentation of patients with lung injuries associated with vaping, and other special considerations Clinical presentation of patients with lung injuries associated with vaping has included shortness of breath, fever, cough, chest pain and gastrointestinal symptoms (nausea, vomiting, abdominal pain), typically with radiographic abnormalities, in the setting of recent or active use of nicotine or THC vaping. Other symptoms may includeheadache and weight loss. Symptoms generally progress over days to weeks. Severity of imaging results may be variable, but often chest radiographs demonstrate bilateral opacities and CT imaging demonstrates diffuse ground glass opacification. Inflammatory markers are typically elevated. Infectious, rheumatologic and other disease process evaluations are usually negative or do not fully explain the extent of lung disease otherwise seen. Patients often require hospital admission for hypoxia and some require ventilator support.

Close follow-up advised Many patients seek care as an outpatient at least once prior to hospital admission. Because symptoms can progress without therapy, patients who do not appear to have a vaping-related lung injury at the time of initial clinical encounter or who are presenting early in the clinical course require close follow-up. It is strongly recommended to follow-up with these patients within 24 to 48 hours. Consultation with specialists as needed is recommended.

Steroids and other treatment Clinical improvement of patients has been reported with corticosteroid use. Currently there is insufficient outcome evidence to recommend use of steroids on a routine basis. The decision to use corticosteroids should be made based on risks and benefits and the likelihood of other etiologies. Aggressive supportive care is warranted, and the decision to use or defer corticosteroids may benefit from consultation with pulmonology and medical toxicology. Consider lung function testing at follow up or referral to a pulmonologist. Referral to addiction medicine should also be considered. Please consult with addiction specialists in your area.

• Report suspected cases to your local health department or the Utah Department of Health (UDOH) as soon as possible by one of these methods:

• Call UDOH at улмπроуπ6191 ƻNJ мπуууπ9tLπ¦¢!I όотпπуунпύ.

• Fax the EVALI Case Report Form to 8лмπроуπ9923Φ

• Email the EVALI Case Report Form to epi@utah.gov.

Resources• CDC EVALI Guidance for Clinicians: https://www.cdc.gov/mmwr/volumes/68/wr/mm6841e3.htm

• Utah Department of Health Lung Injury Outbreak: https://health.utah.gov/lung-disease-investigation

• Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use–Associated LungInjuries — United States, October 2019 https://www.cdc.gov/mmwr/volumes/68/wr/mm6843e1.htm?s_cid=mm6843e1_e&deliveryName=USCDC_921-DM11790

• CDC Health Advisory (HAN), Issued 8/30/19: https://emergency.cdc.gov/han/han00421.asp

• CDC Guidance for Clinicians: Clinician Outreach and Communication Activity (COCA) Clinical Action Message:https://emergency.cdc.gov/newsletters/coca/081619.htm

• For Healthcare Providers, CDC 10/28/2019: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/healthcare-providers/index.html

• Evaluating and Caring for Patients with Suspected E-cigarette or Vaping Product Use Associated Lung Injury (EVALI)https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease/healthcare-providers/pdfs/evaluating-caring-evali-patients.pdf

• Drop-boxes are available at many local Sheriff Stations 24-hours a day and are a safe and confidential way to discardof vaping related products. http://utahtakeback.org/

•

Clinician Guidance for E-cigarette or Vaping Product Use Associated Lung Injury (EVALI) Clinical Sample Collection Guidelines The Utah Department of Health (UDOH), Utah Public Health Laboratory (UPHL), Local Health Departments (LHDs), and the Centers for Disease Control and Prevention (CDC) are requesting clinical samples for reported cases. When samples are available and clinically indicated, please consider sending the following clinical samples to UPHL. Samples can be forwarded using standard couriers and packaging. Each sample should include a Lung Disease Investigation Sample Request Form. Contact UDOH at 801-538-6191 or rcheng@utah.gov with any questions.

Blood samples 1. For each patient, collect up to 8 mL of blood in two (2) 4-mL PURPLE-top (K2 -EDTA) glass or plastic tubes.

If only 3-mL tubes are available, three (3) 3-mL tubes may be collected. NOTE: DO NOT use gel separators.2. Mix contents of tubes by inverting them 5 or 6 times.3. Label tubes in order of collection. Example: #1, #2, #3.4. Place a barcode label on each tube so that the barcode looks like a ladder when the tube is upright.5. Store blood samples at 1ºC to 10ºC. DO NOT FREEZE if prompt transfer to state lab is anticipated.6. If transfer to state lab is expected to be longer than six (6) hours. Separate plasma from whole blood cells

within six (6) hours of collection. Aliquot plasma into cryotubes.

Urine samples 1. For each patient, store 40 to 60 mL of urine in a screw-cap urine cup.2. Place barcoded label on the cup when upright; the barcode will look like a ladder.3. Indicate on the cup how the sample was collected if the method was other than “clean catch.” (Example:

catheterization)4. Store urine samples in the freezer. Freezer temperatures of -20ºC or lower are recommended.

Bronchoalveolar lavage fluid (BAL fluid) 1. Optimal timing. These specimens may be obtained at any time during the clinical course, but ideally prior

to initiation of antimicrobial or steroid therapy. If antibiotics or steroids have been initiated, course andduration should be noted.

2. Specimen collection: BAL fluida. Collect specimens in sterile containers.b. BAL fluid should undergo culture and routine centrifugation followed by cellular analyses and

cytopathology, including lipid and other staining, as clinically indicated at the local institution.

Lung biopsy tissue specimens 1. The decision to perform a lung biopsy is at the discretion of the clinical treatment team. This will include

consultation with pulmonary, critical care, or other specialties.2. Initial evaluation of biopsy tissues at the clinical institution should be guided by consultation with these

specialties and pathology specialists.3. Evaluation can include lipid staining on fresh lung tissues, histopathologic evaluation of formalin-fixed,

paraffin-embedded (FFPE) tissues, and testing for possible infectious etiologies.4. CDC can receive formalin-fixed (wet) tissues or FFPE lung tissue blocks for evaluation, if available from a

biopsy procedure.

Bureau of Epidemiology PO Box 142104, Salt Lake City, UT 84114 www.health.utah.gov/epi

Fax completed form to: 801-538-9923 Email completed form to: epi@utah.gov Cases may also be reported by phone: 801-538-6191 11/2019

E-cigarette or Vaping Product Use Associated Lung Injury (EVALI)Preliminary Case Report Form

Date form completed: ___________________ Clinician location (hospital, clinic): _________________

Clinician name: _________________________ Clinician phone number: _________________________

Date reported to public health: ____________

Full name: ______________________________________________________________________________

Medical record number: __________________ Date of birth: ________________ Gender: M F

Ethnicity: Hispanic Non-Hispanic Race: White African-American Asian/API Other ________

Phone number: ___________________

Street address: _____________________________ City: _____________________ZIP: _______________

Any e-cigarette use reported: Yes No (vaping, dabbing, etc.)

Any THC vaping reported? Yes No Any nicotine vaping reported? Yes No

Was there an alternative plausible diagnosis that was not EVALI? Yes No

If yes, (specify) _________________________________________________________________

Did the clinical team caring for the patient believe EVALI contributed to underlying lung injury? Yes No

Admitted to hospital? Yes No Date of hospital admission: ___________________

Date of discharge: _________________

Imaging CT chest Chest X-ray Both None

Infiltrates/opacities present Yes No

Impression: (copy the Summary/Impression from the CT/CXR radiologist report or attach a copy of report)

Infectious Disease Testing + - Not Done + - Not Done

Respiratory Viral Panel Blood cultures

Influenza Strep pneumoniae

Legionella Mycoplasma pneumoniae

Other testing or additional detail:

REPORTING INFORMATION

PATIENT INFORMATION

PATIENT INHALATIONAL USE IN THE PAST 90 DAYS (ASK PATIENT OR PROXY, IF PATIENT UNABLE TO ANSWER)

Page 1 – The data elements on this page are necessary for public health monitoring.

Please let patient know public health may try to follow-up with patient for additional information.

Bureau of Epidemiology PO Box 142104, Salt Lake City, UT 84114 www.health.utah.gov/epi

Fax completed form to: 801-538-9923 Email completed form to: epi@utah.gov Cases may also be reported by phone: 801-538-6191 11/2019

Supplemental Information (collect information, if available)

Any combustible cigarette smoking (nicotine)? Yes No (includes cigarettes, cigars, etc.)

Any combustible marijuana? Yes No (includes any non-e-cigarette marijuana use)

Date of last e-cigarette THC use: _________________

Frequency of e-cigarette THC use (average # times/day): ________ (whole #)

If yes, please list product brands: _________________________________________________

# of brands: ___________________

What devices were used for THC? __________________________________

Where was THC product purchased?

Dealer Friend Website Social media app Convenience store

Vape shop Out-of-state dispensary Other ____________________________________

Date of last e-cigarette nicotine use: ______________

Frequency of e-cigarette nicotine use (average # times/day): ________________ (whole #)

If yes, please list brands: _________________________________________________________

# of brands: ___________________

What devices used for nicotine?

Disposable e-cigarette or vaping device

E-cigarette with pre-filled or refillable cartridges

E-cigarette with tank that can be refilled with liquids (e.g., mods)

E-cigarettes with pre-filled or refillable “pods” or pod cartridges (e.g., JUUL, Suorin)

Other ______________________________________________________________________

Where was nicotine product purchased?

Dealer Friend Website Social media app Convenience store

Vape shop Out-of-state dispensary Other ___________________________________

Any other e-cigarette exposures? Yes No

If yes, please describe (e.g., CBD, Unknown): _________________________________________

Gastrointestinal symptoms: N/A Nausea Vomiting Abdominal pain Other______________ Onset date: _________________

Respiratory symptoms: N/A Cough Shortness of breath Hypoxia Pleuritic chest pain

Other ____________________ Onset date: _________________

Constitutional symptoms: N/A Fever Chills Tachycardia Malaise Other ____________

Onset date: _________________

PATIENT INHALATIONAL USE IN THE PAST 90 DAYS (ASK PATIENT OR PROXY, IF PATIENT UNABLE TO ANSWER)

PATIENT CLINICAL DATA

Page 2 – The data elements on this page are supplemental and help inform the EVALI investigation.

Please let patient know public health may try to follow-up with patient for additional information.